The University of Chicago Header Logo

Connection

Harvey M. Golomb to Interferon-alpha

Back to Details
This is a "connection" page, showing publications Harvey M. Golomb has written about Interferon-alpha.
Harvey M. Golomb
Connection Strength
1.319
Interferon-alpha
  1. Hairy cell leukemia: treatment successes in the past 25 years. J Clin Oncol. 2008 Jun 01; 26(16):2607-9.
    View in: PubMed
    Score: 0.292
  2. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995 Apr; 13(4):974-82.
    View in: PubMed
    Score: 0.117
  3. Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986. Leuk Lymphoma. 1994; 14 Suppl 1:89-93.
    View in: PubMed
    Score: 0.107
  4. Acute myeloid leukaemia following interferon-alfa treatment of hairy cell leukaemia. Br J Haematol. 1993 Mar; 83(3):519-20.
    View in: PubMed
    Score: 0.101
  5. Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986. Leukemia. 1992 Nov; 6(11):1177-80.
    View in: PubMed
    Score: 0.099
  6. Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res. 1992 Mar 01; 52(5):1056-66.
    View in: PubMed
    Score: 0.095
  7. Duration of response after interferon treatment of hairy cell leukemia. Blood. 1990 Jun 15; 75(12):2465-7.
    View in: PubMed
    Score: 0.084
  8. Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. J Natl Cancer Inst. 1989 Aug 02; 81(15):1172-4.
    View in: PubMed
    Score: 0.079
  9. Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b. Semin Oncol. 1988 Oct; 15(5 Suppl 5):7-9.
    View in: PubMed
    Score: 0.075
  10. Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia. 1995 Jul; 9(7):1116-20.
    View in: PubMed
    Score: 0.030
  11. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest. Cancer Chemother Pharmacol. 1995; 35(4):304-12.
    View in: PubMed
    Score: 0.029
  12. Do we know the treatment of choice for hairy cell leukemia? Ann Oncol. 1994 Oct; 5(8):676-7.
    View in: PubMed
    Score: 0.028
  13. Increased incidence of second neoplasms in patients treated with interferon alpha 2b for hairy cell leukemia: a clinicopathologic assessment. Blood. 1994 May 15; 83(10):2931-8.
    View in: PubMed
    Score: 0.028
  14. Concomitant chemoradiotherapy for non-small cell lung cancer. Lung Cancer. 1994 Mar; 10 Suppl 1:S253-61.
    View in: PubMed
    Score: 0.027
  15. Hairy cell leukaemia. Baillieres Clin Haematol. 1993 Dec; 6(4):887-98.
    View in: PubMed
    Score: 0.027
  16. Expression of the IFN alpha receptor in hairy cell leukaemia. Br J Haematol. 1992 Nov; 82(3):541-6.
    View in: PubMed
    Score: 0.025
  17. The treatment of hairy cell leukemia: an update. Leukemia. 1992; 6 Suppl 2:24-7.
    View in: PubMed
    Score: 0.023
  18. Cost-benefit analysis of interferon alfa-2b in treatment of hairy cell leukemia. J Natl Cancer Inst. 1989 Apr 19; 81(8):594-602.
    View in: PubMed
    Score: 0.019
  19. Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. J Clin Oncol. 1988 Nov; 6(11):1714-21.
    View in: PubMed
    Score: 0.019
  20. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood. 2000 Nov 01; 96(9):2981-6.
    View in: PubMed
    Score: 0.011
  21. Heat shock proteins in normal and leukemic blood cells. J Interferon Res. 1989 Apr; 9(2):195-204.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.